Abstract: A humidification system can include a heater base, a humidification chamber, and a breathing circuit. A cartridge can be removably coupled to the heater base. The cartridge can include various sensors, probes, sensor wire connectors, heater wire connectors, and/or other features. The cartridge can include features configured to mate with corresponding features on the humidification chamber and the heater base. The cartridge includes a memory, such as an EEPROM, or other suitable storage device. When the cartridge is installed on the heater base, the memory is electrically connected to a processor and/or memory of the heater base. Various models of cartridges can be produced for use with different humidification chambers, breathing circuits, and/or therapies. A connector can be configured to couple an inspiratory conduit to an outlet port of the humidification chamber. The connector can provide a pneumatic connection to the outlet port and an electrical connection to the cartridge.

Abstract: The present technology is generally directed to vent stack lids and associated systems and methods. In particular, several embodiments are directed to vent stack lids having improved sealing properties in a coke processing system. In a particular embodiment, a vent stack lid comprises a first lid portion proximate to and at least partially spaced apart from a second lid portion. The vent stack lid further comprises a first sealing portion coupled to the first lid portion and a second sealing portion coupled to the second lid portion. In several embodiments, the second sealing portion at least partially overlaps the first sealing portion over the space between the first and second lid portions. In further embodiments, at least one of the first or second sealing portions includes layers of tadpole seals, spring seals, rigid refractory material, and/or flexible refractory blanket.

Abstract: The present disclosure relates to the use of stimulators of soluble guanylate cyclase (sGC), pharmaceutically acceptable salts thereof and pharmaceutical formulations or dosage forms comprising them, alone or in combination with one or more additional agents, for the treatment of various CNS diseases, wherein an increase in sGC stimulation, or an increase in the concentration of nitric oxide (NO), or cyclic guanosine 3?,5?-monophosphate (cGMP) or both, or an upregulation of the NO pathway is desirable.

Abstract: The present disclosure relates to stimulators of soluble guanylate cyclase (sGC), pharmaceutical formulations comprising them and their uses thereof, alone or in combination with one or more additional agents, for treating various diseases, wherein an increase in the concentration of nitric oxide (NO) or an increase in the concentration of cyclic Guanosine Monophosphate (cGMP), or both, or an upregulation of the NO pathway is desirable.

Abstract: A wheel brake is disclosed to communicate with at least one wheel of a wheeled article (e.g., a wagon) to prevent the wheel from rotating and the wheeled article from rolling away. A toothed locking gear is attached to a hub of the wheel so that the wheel and the locking gear rotate together. A brake pedal of the wheel brake is pivotally connected to the wagon at a wheel bracket thereof to be rotatable in response to a pushing force applied thereto towards and into locking engagement with the locking gear. A coupler (e.g., a locking pin) of the brake pedal is received between a successive pair of teeth of the toothed locking gear, such that the locking gear and the wheel to which the locking gear is attached are unable to rotate, whereby the wheeled article is held in place.

Abstract: The present disclosure relates to the use of stimulators of soluble guanylate cyclase (sGC), pharmaceutically acceptable salts thereof and pharmaceutical formulations or dosage forms comprising them, alone or in combination with one or more additional agents, for the treatment of various CNS diseases, wherein an increase in sGC stimulation, or an increase in the concentration of nitric oxide (NO), or cyclic guanosine 3?,5?-monophosphate (cGMP) or both, or an upregulation of the NO pathway is desirable.

Abstract: The present disclosure relates to stimulators of soluble guanylate cyclase (sGC), pharmaceutical formulations comprising them and their uses thereof, alone or in combination with one or more additional agents, for treating various diseases, wherein an increase in the concentration of nitric oxide (NO) or an increase in the concentration of cyclic Guanosine onophosphate (cGMP), or both, or an CN upregulation of the NO pathway is desirable. The compounds are of Formula I: or a pharmaceutically acceptable salt thereof, wherein each of Y1, Y2, Y3, Y4, Y5, Y6, Y7, Y8 and Y9 is independently selected from hydrogen and deuterium, as well as pharmaceutical compositions, methods and uses thereof.

Abstract: Compounds of Formulae I? and I are described, which are useful as stimulators of sGC, particularly NO-independent, heme-dependent stimulators. These compounds are also useful for treating, preventing or managing various disorders that are herein disclosed.

Abstract: Disclosed is a wagon adapted to be folded between an expanded open configuration and a compact collapsed configuration. A basket of the wagon is carried by a collapsible frame having height adjustment legs at the corners thereof. Height adjustment guides that stand upwardly from wheel brackets are slidable up and down through respective height adjustment legs such that the elevation of the frame and the basket carried thereby can be selectively changed. Rotatable handles are pivotally attached to the wagon at the front and the rear of the wagon frame. Telescoping canopy support assemblies are removably received downwardly within and upwardly from respective ones of the height adjustment guides to hold a removable canopy over the wagon basket. A collapsible wagon frame support has a set of rotatable frame reinforcing rods pivotally and detachably connected by ball and socket couplings to the bottom of the wagon frame at the corners thereof.

Abstract: The present disclosure relates to stimulators of soluble guanylate cyclase (sGC), pharmaceutical formulations comprising them and their uses thereof, alone or in combination with one or more additional agents, for treating various diseases, wherein an increase in the concentration of nitric oxide (NO) and/or an increase in the concentration of cyclic Guanosine Monophosphate (cGMP) might be desirable.

Abstract: The present disclosure relates to stimulators of soluble guanylate cyclase (sGC), pharmaceutical formulations comprising them and their uses thereof, alone or in combination with one or more additional agents, for treating various diseases, wherein an increase in the concentration of nitric oxide (NO) or an increase in the concentration of cyclic Guanosine Monophosphate (cGMP), or both, or an upregulation of the NO pathway is desirable.

Abstract: Compounds of Formulae I? and I are described, which are useful as stimulators of sGC, particularly NO-independent, heme-dependent stimulators. These compounds are also useful for treating, preventing or managing various disorders that are herein disclosed.

Abstract: The present disclosure relates to stimulators of soluble guanylate cyclase (sGC), pharmaceutical formulations comprising them and their uses thereof, alone or in combination with one or more additional agents, for treating various diseases, wherein an increase in the concentration of nitric oxide (NO) and/or an increase in the concentration of cyclic Guanosine Monophosphate (cGMP) might be desirable. Various compounds are disclosed, including those of Formula (I).

Abstract: Compounds are described, which are useful as stimulators of sGC, particularly NO-independent, heme-dependent stimulators. These compounds are also useful for treating, preventing or managing various disorders that are herein disclosed.

Abstract: The present disclosure relates to stimulators of soluble guanylate cyclase (sGC), pharmaceutical formulations comprising them and their uses thereof, alone or in combination with one or more additional agents, for treating various diseases, wherein an increase in the concentration of nitric oxide (NO) or an increase in the concentration of cyclic Guanosine Monophosphate (cGMP), or both, or an upregulation of the NO pathway is desirable.

Abstract: This invention relates to deuterated compounds of Formula I, and pharmaceutically acceptable salts thereof. or a pharmaceutically acceptable salt thereof, wherein each of Y1, Y2, Y3, Y4, Y5a, Y5b, Y6, Y7, Y8, Y9, Y10, Y11a, Y11b, Y12a and Y12b is independently selected from hydrogen and deuterium, as well as pharmaceutical compositions, methods and uses thereof.

Abstract: This invention relates to deuterated compounds of Formula I, and pharmaceutically acceptable salts thereof. or a pharmaceutically acceptable salt thereof, wherein each of Y1, Y2, Y3, Y4, Y5a, Y5b, Y6, Y7, Y8, Y9, Y10, Y11a and Y11b is independently selected from hydrogen and deuterium, as well as pharmaceutical compositions, methods and uses thereof.

Abstract: The present disclosure relates to stimulators of soluble guanylate cyclase (sGC), pharmaceutical formulations comprising them and their uses thereof, alone or in combination with one or more additional agents, for treating various diseases, wherein an increase in the concentration of nitric oxide (NO) or an increase in the concentration of cyclic Guanosine Monophosphate (cGMP), or both, or an upregulation of the NO pathway is desirable.

Abstract: The present patent application discloses at least the compounds according to Formula I? shown below, or pharmaceutically acceptable salts thereof, wherein ring D, ring A, ring E, JB, n, JD, J, X, Z, Z1, RC1, RC2, Y, R9, o and W are as defined herein.

Abstract: Compounds of Formulae I? and I are described, which are useful as stimulators of sGC, particularly NO-independent, heme-dependent stimulators. These compounds are also useful for treating, preventing or managing various disorders that are herein disclosed.